4DMedicalFDMDF -6.67%46 Equity-to-Asset is -0.20 as of Dec. 2025. GuruFocus rates FDMDF with a GF Score™ of 46/100 and a GF Value™ of $0.87 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 854 Medical Devices & Instruments companies, 4DMedical ranks worse than 94.15% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. 4DMedical's Total Stockholders Equity for the quarter that ended in Dec. 2025 was $-18.87 Mil. 4DMedical's Total Assets for the quarter that ended in Dec. 2025 was $92.72 Mil.
Therefore, 4DMedical's Equity to Asset Ratio for the quarter that ended in Dec. 2025 was -0.20.
The historical rank and industry rank for 4DMedical's Equity-to-Asset or its related term are showing as below:
FDMDF'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.75 Med: 0.68 Max: 0.95
Current: -0.2
During the past 6 years, the highest Equity to Asset Ratio of 4DMedical was 0.95. The lowest was -0.75. And the median was 0.68.
FDMDF's Equity-to-Asset is ranked worse than 94.15% of 854
companies
in the Medical Devices & Instruments industry
Industry Median: 0.65
vs FDMDF: -0.20
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
4DMedical Equity-to-Asset Related Terms
4DMedical Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for 4DMedical's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FDMDF vs ABT, SYK, MDT: Equity-to-Asset Comparison
For the Medical Devices subindustry, 4DMedical's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
4DMedical Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, 4DMedical's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where 4DMedical's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
4DMedical's Equity to Asset Ratio for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
4DMedical (FDMDF) has a Equity-to-Asset of -0.20 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on 4DMedical and its competitors. According to the industry distribution chart, 4DMedical ranks #804 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 94.1%.
Is 4DMedical's Equity-to-Asset too high?
4DMedical's current Equity-to-Asset is -0.20. Based on the distribution chart, 4DMedical ranks #804 out of 854 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, 4DMedical has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 4DMedical's Equity-to-Asset compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, 4DMedical ranks #804 out of 854 companies for Equity-to-Asset. This places 4DMedical in the lower half of its industry. The industry median Equity-to-Asset is 0.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.65, based on 854 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on 4DMedical and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 4DMedical's current Equity-to-Asset is -0.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 4DMedical stock overvalued right now?
Based on GuruFocus' analysis, 4DMedical (FDMDF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.87, compared to a current price of $2.80 — trading 221.8% above its estimated fair value. The current Equity-to-Asset is -0.20. 4DMedical's overall GF Score™ is 46/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For 4DMedical (FDMDF), the current Equity-to-Asset is -0.20 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 4DMedical (FDMDF) Overvalued in 2026?
Based on GuruFocus' analysis, 4DMedical stock appears to be overvalued.
The current stock price of $2.80 is trading 221.8% above its estimated GF Value™ of $0.87.
GuruFocus considers 4DMedical to be Significantly Overvalued.
Key valuation signals for FDMDF:
Equity-to-Asset: -0.20
GF Value™: $0.87 vs. price of $2.80 (221.8% above fair value)
No single metric tells the full story. See the FDMDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
4DMedical Ltd is a company focused on medical research technology and the development of a non-invasive respiratory imaging solution using four-dimensional imaging. The four-dimensional lung imaging technology utilizes mathematical models and algorithms to convert X-ray scans into quantitative data, aiding physicians in managing patients with respiratory and lung diseases.
46GF Score
Get the complete analysis for FDMDF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FDMDF has been successfully added to your 
